PDSB - PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

2024-01-26 18:59:32 ET

Summary

• Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024.
• The global oral cancer treatment market is expected to reach $2.74 billion by 2030.
• It is said that nearly 80% to 90% of all oropharynx tumors are HPV-positive.
• Initiation of phase 3 VERSTILE-003 study, using PDS0101 + KEYTRUDA to treat patients with recurrent or metastatic head and neck squamous cell carcinoma, expected Q1 of 2024.

PDS Biotechnology ( PDSB ) was able to submit an IND to begin its phase 3 VERSATILE-003 study, using PDS0101 + KEYTRUDA to treat patients with recurrent or metastatic head and neck squamous cell carcinoma [HNSCC]. I briefly spoke about this in a prior Seeking Alpha article entitled " PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study ". Since then, it has been able to receive guidance from the FDA on a proposed design of a late-stage trial. With this feedback, it anticipates that it will begin the VERSATILE-003 study in Q1 of 2024. The thing is that while the company continues to make progress on this late-stage program, there is another catalyst to look forward to....

For further details see: